menu
    • menu

    Company profile for Oncolytics Biotech

    NEW Drugs in Dev: 2
    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Oncolytics Biotech Inc. is developing pelareorep, a safe and well-tolerated intravenously delivered immuno-oncolytic virus (IOV) that kills cancer through a unique mechanism of action with two components, selective tumor lysis and activation of the innate and adaptive immune systems, creating an inflamed phenotype to treat a variety of solid tumors and hematological malignancies.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Oncolytics BiotechCanada Flag
    Country
    Country
    Canada
    Address
    Address
    210, 1167 Kensington Crescent NW Calgary, Alberta T2N 1X7
    Telephone
    Telephone
    (403) 670-7377
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.oncolyticsbiotech.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/oncolytics-biotech-inc./
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    ASPEN

    ASPEN

    Not Confirmed

    envelop Contact Supplier

    ASPEN

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    How 2026's Clinical Leaders Are Beating Cancer Benchmarks
    How 2026's Clinical Leaders Are Beating Cancer Benchmarks

    27 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/registration-ready-how-2026s-clinical-leaders-are-beating-cancer-benchmarks-302671414.html

    PR NEWSWIRE
    27 Jan 2026
    Share Share
    Oncolytics Biotech Reveals Shareholders' Meeting Outcome
    Oncolytics Biotech Reveals Shareholders' Meeting Outcome

    15 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/15/3219978/0/en/Oncolytics-Biotech-Announces-Results-of-Special-Meeting-of-Shareholders.html

    GLOBENEWSWIRE
    15 Jan 2026
    Share Share
    Oncolytics Bio Names McAdory as EVP, Yujun Wu as Biostats Lead
    Oncolytics Bio Names McAdory as EVP, Yujun Wu as Biostats Lead

    14 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/14/3218710/0/en/Oncolytics-Biotech-Appoints-John-McAdory-as-EVP-of-Strategy-and-Operations-and-Yujun-Wu-to-Lead-Biostatistics.html

    GLOBENEWSWIRE
    14 Jan 2026
    Share Share
    Oncolytics Biotech Reveals Pelareorep Plus Atezolizumab Efficacy
    Oncolytics Biotech Reveals Pelareorep Plus Atezolizumab Efficacy

    12 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/12/3216966/0/en/Oncolytics-Biotech-Announces-Updated-Clinical-Data-from-GOBLET-Cohort-4-Demonstrating-Activity-of-Pelareorep-Plus-Atezolizumab-in-Third-Line-Anal-Cancer.html

    GLOBENEWSWIRE
    12 Jan 2026
    Share Share
    Oncolytics Biotech Details Move To Nevada For Strategic Reasons
    Oncolytics Biotech Details Move To Nevada For Strategic Reasons

    09 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/09/3216107/0/en/Oncolytics-Biotech-Outlines-Strategic-Rationale-for-Proposal-to-Change-Jurisdiction-of-Incorporation-to-Nevada.html

    GLOBENEWSWIRE
    09 Jan 2026
    Share Share
    Oncolytics Biotech Updates Intellectual Property Strategy
    Oncolytics Biotech Updates Intellectual Property Strategy

    08 Jan 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-01-08/oncolytics-biotech-provides-update-on-intellectual-property-strategy-and-patent-filings

    PHARMIWEB
    08 Jan 2026
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search